Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trial
Abstract
Aim of investigation. To determine efficacy and safety of budesonide and prednisolone at alcoholinduced hepatitis (AH) of severe course on development of inflammation and results of the functional hepatic tests, to estimate treatment response and short-term survival rate of patients.
Material and methods. Original study included 37 patients with acute AH, that have been selected from 3 medical centers and randomized in two groups. The first group included 17 patients (7 men, 10 women, mean age 46,53±11,01 years). Median of daily alcohol dose was 77 g; 25th and 75th percentiles were 55 and 96 g; duration of intake 13,41±8,55 years. Mean Maddrey index (MI) was 65,22 (37,2 to 145,4). The second group included 20 patients (16 men, 4 women, mean age was 46,5±11,89 years). A median of used alcohol consumption was 70,55 g/day (25th 75th percentiles were 37 and 88 g), duration of intake — 16,85±13,32 years. Mean MI – 58,11 (32,1 to 121,7). Groups were comparable for main clinical and laboratory features. In the first group oral budesonide 9 mg/day per os was applied, in the second – oral prednisolone 40 mg/day. Lille index was used as treatment response criterion. Following statistical criteria were used for data processing: χ2, Wilcoxon, Mann-Whitney, Kaplan – Mayer method.
Results. At comparison of treatment efficacy (р=0,810) and short-term survival rate (р=0,857) no significant differences were obtained. At treatment safety analysis in the first group adverse events (AE) were registered in 23,5% of cases (in 4 of 17 patients), in the second group – in 70% (in 14 of 20 patients, р=0,011). Hepatorenal syndrome was significantly more frequent in the second group (р=0,033).
Conclusions. Short-time survival in budesonide and prednisolone group does not differ significantly. At application of prednisolone frequency of AE is higher as a whole, particularly – hepatorenal syndrome.
About the Authors
I. I. Komkova
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
M. V. Mayevskaya
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
V. T. Ivashkin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Байкова И.Е., Никитин И.Г., Гогова Л.М. Алкогольная болезнь печени // Рус. мед. журн. 1057.
2. Болезни печени и желчевыводящих путей: Руководство для врачей / Под ред. В.Т. Ивашкина. – 2-е изд. – М.: Изд. Дом «М-вести», 2005.
3. Буеверов А.О., Маевская М.В., Ивашкин В.Т. Дифференцированный подход к лечению алкогольных поражений печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2005. – Т. 15, № 5. – С. 4–10.
4. Зейтц Гельмут. Алкогольная болезнь печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2001. – Т. 11, № 4. – С. 62–64. 5. Ивашкин В.Т., Маевская М.В. Алкогольно-вирусные заболевания печени. – М.: Литтерра, 2007. – С. 85–118.
5. Калинин А.В. Алкогольная болезнь печени // Фарматека. – 2005. – 1 (97). – С. 48–55.
6. Лопаткина Т.Н., Танащук Е.Л. Алкоголь и хроническая HCV-инфекция // Информ. бюл.: Вирусные гепатиты. Достижения и перспективы. – 2001. – № 1 (8). – С. 11–14.
7. Маевская М.В. Алкогольная болезнь печени // Клин. перспективы гастроэнтерол. гепатол. – 2001. – № 1. – С. 4–8.
8. Маевская М.В., Морозова М.А., Ивашкин В.Т. Алгоритм ведения пациентов с алкогольной болезнью печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2007. – Т. 17, № 6. – С. 1–10.
9. Наследов А. SPSS 19 профессиональный статистический анализ данных. – Спб.: Питер, 2011.
10. Подымова С.Д. Болезни печени. – М.: Медицина,1993. – 548 с.
11. Хазанов А.И. Алкогольная болезнь печени // Рос. мед. вести. – 2002. – Т. 7, № 1. – С. 18–24.
12. Хазанов А.И. Современные проблемы вирусных и алкогольных болезней печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2002. – Т. 12, № 2. – С. 6–15.
13. Хазанов А.И., Васильев А.П., Пехташев С.Г. и др. Значение основных и добавочных этиологических факторов в развитии HCV и HBV-циррозов печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. –2001. – Т. 11, № 4. – С. 8–12.
14. Хазанов А.И., Плюснин С.В., Белякин С.А. и др. Хроническая интоксикация алкоголем и заболевание печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2009. – Т. 19, № 1. – С. 43–52.
15. Bellentani S, Saccocio G, Costa G, et al. Drinking habits as cofactor of risk for alcohol induced liver damage. Gut. 1997; 41:845–50.
16. Bush KR, Bradley KA, McDonell MB, et al. Screening for problem drinking: Comparison of CAGE and AUDIT. Ambulatory care quality improvement project. J Gen Intern Med. 1998; 13 (6):379–88.
17. Espinoza P, Ducot B, Pelletier G, et al. Interobserver agreement in the physical diagnosis of alcoholic liver disease. Dig Dis Sci. 1987; 32 (3):244–7.
18. Fernández-Checa JC. Alcohol-induced liver disease: when fat and oxidative stress meet. Ann Hepatol. 2003;2(2):69–75.
19. Hart C, Morrison D, Batty G, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010;340:1240.
20. Jonsson E, Nilsson T. Alcohol comsumption in monozygotic and dizygotic pairs of twins. Nord Hyg Tidskr. 1968; 49 (1):21–5.
21. Limuro Y, Frankenberg M, Arteel G, et al. Female rats exhibit greater susceptibility to early alcohol-induced liver injury than males. Am J Physiol. 1997; 272:1186–94.
22. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007; 45 (6):1348–54.
23. Maddrey WC, Carithers RL Jr, Herlong HF, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989; 110:685–90.
24. Maturin P, Lucey MR. Management of alcoholic hepatitis. J. Hepatol. 56, suppl. 1.
25. Naveau S, Cassard-Doulcier AM, Njiké-Nakseu M, et al. Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease. J Hepatol. 2010; 52(6):895–902. Epub 2010 Mar 24.
26. Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25(1):108–11.
27. O’Connor PG, Schottenfeld RS. Patients with alcohol problems. N Engl J Med. 1998; 338 (9):592–602. Review.
28. O’Shea RS, Dasarathy S, McCullough AJ, et al. Alcoholic liver disease. AASLD practice guidelines. Hepatology. 2010; 51(1):307–28.
29. Sheth M, Riggs M, Patel T. Utility of the Mayo EndStage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002; 2:2.
30. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver – the link between adipocytes and hepatocytes. Digestion. 2011; 83(1–2):124–33. Epub 2010 Nov 1.
31. Yin M., Ikejima K., Wheeler M, et al. Estrogen is involved in early alcohol-induced liver injury in rat enteral feeding model. Hepatology. 2000; 31:117–23.
Review
For citations:
Komkova I.I., Mayevskaya M.V., Ivashkin V.T. Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trial. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;23(4):37-44. (In Russ.)
Views:
204
Email this article 
